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Abstract
Omega-3 and n-6 fatty acids are biosynthetic precursors to lipid mediators with antinociceptive
and pronociceptive properties. We conducted a randomized, single-blinded, parallel-group clinical
trial to assess clinical and biochemical effects of targeted alteration in dietary n-3 and n-6 fatty
acids for treatment of chronic headaches. After a 4-week preintervention phase, ambulatory
patients with chronic daily headache undergoing usual care were randomized to 1 of 2 intensive,
food-based 12-week dietary interventions: a high n-3 plus low n-6 (H3-L6) intervention, or a low
n-6 (L6) intervention. Clinical outcomes included the Headache Impact Test (HIT-6, primary
clinical outcome), Headache Days per month, and Headache Hours per day. Biochemical
outcomes included the erythrocyte n-6 in highly unsaturated fatty acids (HUFA) score (primary
biochemical outcome) and bioactive n-3 and n-6 derivatives. Fifty-six of 67 patients completed the
intervention. Both groups achieved targeted intakes of n-3 and n-6 fatty acids. In intention-to-treat
analysis, the H3-L6 intervention produced significantly greater improvement in the HIT-6 score
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(−7.5 vs −2.1; P < 0.001) and the number of Headache Days per month (−8.8 vs −4.0; P = 0.02),
compared to the L6 group. The H3-L6 intervention also produced significantly greater reductions
in Headache Hours per day (−4.6 vs −1.2; P = 0.01) and the n-6 in HUFA score (−21.0 vs −4.0%;
P < 0.001), and greater increases in antinociceptive n-3 pathway markers 18-hydroxy-
eicosapentaenoic acid (+118.4 vs +61.1%; P < 0.001) and 17-hydroxy-docosahexaenoic acid
(+170.2 vs +27.2; P < 0.001). A dietary intervention increasing n-3 and reducing n-6 fatty acids
reduced headache pain, altered antinociceptive lipid mediators, and improved quality-of-life in this
population.
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1. Introduction
Chronic daily headache (CDH), defined here as the presence of headaches lasting 4 hours or
more for 15 or more days per month over at least 3 months, is a heterogeneous group of
debilitating chronic pain syndromes affecting an estimated 10 million adults in the United
States [10,45]. Loss of work and medical expenses add up to billions of dollars per year
[14,38]. The term CDH encompasses several primary headache types including chronic
migraine and chronic tension-type headache [10,45], which together account for up to 40%
of patients presenting to headache specialty clinics. Conventional treatment relies heavily on
medications that often provide only partial or transient relief and can be associated with
significant side effects and costs [6–8,31,57,59]. Many chronic headache patients continue
to have frequent headaches and impaired quality of life despite taking numerous pain-related
medications [47,50]. Given the incomplete effectiveness and potential side effects of many
headache medications, it is essential to investigate novel mechanisms and alternative
approaches to manage pain.
1.1. A role for diet in chronic pain?
Omega-6 (n-6) and omega-3 (n-3) fatty acids regulate multiple pain-related biochemical
pathways. As major components of vascular, immune, myelin, glial, and neuronal cell
membranes [46], n-6 and n-3 fatty acids can be converted to lipid mediators with pro- or
antinociceptive properties (eg, endovanilloids, eicosanoids, endocannabinoids, resolvins)
[1,20,34–36,48,58,60]. In general, and with a few notable exceptions [52], lipid mediators
derived from n-6 fatty acids have pronociceptive properties [1,2,19,20,22,35,36,56], while
mediators derived from n-3 fatty acids have antinociceptive properties [32,34,48,58].
Therefore, dietary interventions with targeted alterations in n-6 and n-3 fatty acids may be
able to reduce pain (Fig. 1). However, controlled dietary trials testing pain reduction and
elucidating mechanisms of action in humans are lacking.
We hypothesized that hyperactive metabolism of n-6 linoleic (n-6 LA) and arachidonic (n-6
AA) acids, and insufficient metabolism of n-3 eicosapentaenoic (n-3 EPA) and
docosahexaenoic (n-3 DHA) acids, contribute to headache pathogenesis. Therefore, we
conducted a randomized, parallel-group clinical trial in which we assigned patients with
CDH to either a high n-3 plus low n-6 (H3-L6) dietary intervention or a low n-6 (L6)
intervention for 12 weeks to evaluate whether these targeted dietary alterations would 1)
improve headache-related clinical outcomes; 2) increase n-3 and reduce n-6 fatty acids in
erythrocytes; and 3) increase antinociceptive n-3 derivatives, and reduce pronociceptive n-6
derivatives.
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2. Materials and methods
The trial protocol and detailed descriptions of the dietary interventions are reported
elsewhere [29,41]. Briefly, adult men and women with any primary headache type meeting
our CDH criteria of headaches ≥ 4 hours per day and ≥ 15 days per month for at least 3
months and a headache history of ≥ 2 years under the care of a physician for headache
management, were recruited to participate in an outpatient dietary intervention trial
(Supplementary Table 1). Patients with evidence of a secondary headache disorder attributed
to head and/or neck trauma, cranial or cervical vascular disorder, nonvascular cranial
disorder, substance use or withdrawal, infection, disorder of hemostasis, or headaches
attributed to psychiatric disorder, were not eligible. Participants were enrolled by the study
neurologist. All participants provided written informed consent after the nature and possible
consequences of the trial were explained. During the 4-week preintervention run-in phase,
participants continued their usual care and used an online daily headache diary to record
headache characteristics and medication use. Upon completion of this run-in phase,
participants were randomized to either the H3-L6 intervention or the L6 intervention, to be
maintained for 12 weeks. Participants were advised to continue seeing their regular
headache physician for usual care throughout the trial. The trial was conducted at the
University of North Carolina at Chapel Hill (UNC) from April 2009 to November 2011
(ended when minimum acceptable sample size was met). Trial procedures were approved by
the UNC Institutional Review Board. This trial is registered under ClinicalTrials.gov
(NCT01157208).
2.1. Randomization and masking
Participants were randomized by the dietitian using an on-line, uneditable treatment
assignment algorithm with a random permuted block design using a number sequence (1:1
allocation ratio) generated by a study programmer. Only the dietitian was unmasked by
necessity at randomization in order to assign patients to their group and to administer the
interventions. Participants were provided specific dietary advice and foods in accordance
with their assigned intervention, and were masked to the nature and content of the other
group’s intervention. All other investigators, study and laboratory staff, and each
participant’s personal physician were masked to group assignment for the full duration of
the trial.
2.2. Dietary interventions and nutrient intake assessment
The H3-L6 intervention was designed to reduce dietary n-6 LA, and concurrently increase
dietary n-3 EPA and DHA. The L6 intervention was designed to reduce dietary n-6 LA, and
maintain low n-3 EPA and DHA intakes typical of U.S. diets [4,29]. The interventions were
designed to be equally credible and equivalent with respect to: 1) macronutrient and caloric
intake; 2) the amounts of study foods provided; 3) interactions with the study dietitian and
other investigators; and 4) the intensity and breadth of the dietary advice and intervention
materials [29]. A registered dietitian provided intensive counseling at randomization and at
regular 2-week intervals. Foods meeting nutrient targets were provided to participants
sufficient for 2 meals and 2 snacks per day. Extensive intervention-specific Web-based
materials were developed and made available to participants in order to reinforce dietitian
advice and complement study food provision. Nutrient intakes were assessed for each
participant using 6 unannounced telephone-administered 24-hour recalls – 3 during the 4-
week run-in phase and 3 in the final 4 weeks of the intervention phase. Nutrient values were
estimated using the Nutritional Data System for Research [43], which was updated to
include the fatty acid contents of our laboratory-analyzed study foods to improve accuracy
of intraintervention assessments [29].
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2.3. Analysis of erythrocyte fatty acids
Fasting (>10 hours) blood was collected at the conclusion of the run-in phase, and after 4, 8,
and 12 weeks of diet exposure, in EDTA tubes and immediately centrifuged at 2960 rpm for
15 minutes. Erythrocyte aliquots were prepared and stored at −80°C until analysis.
Following Bligh/Dyer extraction [5], aliquots were heated at 100°C for 1 hour with
methanol containing 14% boron trifluoride to generate fatty acidmethyl ester, which was
then extracted into hexane and analyzed with a gas chromatography/flame ionization
detector gas chromatograph (Agilent 6890; Agilent Technologies, Santa Clara, CA, USA)
equipped with a 30-mDB-free fatty acid phase (DBFFAP) capillary column. Fatty acids
were identified through comparison with a fatty acid methyl ester mixture (GLC-462). Two
composite fatty acid indices [18,51] were calculated. The n-6 in HUFA score, the primary
biochemical outcome, is equal to the proportion of n-6 fatty acids in total highly unsaturated
fatty acids (HUFA). The n-3 index is equal to the sum of erythrocyte n-3 EPA and DHA.
2.4. Analysis of omega-3-derived antinociceptive mediators and pathway markers
The resolvin pathway precursors 18R/S-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid
(18R/S-HEPE) and 17R/S-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (17R/S-
HDHA) derived from EPA and DHA, respectively, and 7S,16R,17S-trihydroxy-4Z,8E,10Z,
12E,14E,19Z-docosahexaenoic acid (RvD2) derived from DHA, were analyzed as
previously described [30]. Briefly, plasma (1 mL) and internal standard leukotriene B4-d4
(80 ng; Cayman Chemicals, Ann Arbor, MI, USA) were acidified to pH 3 with 0.25 M HCl.
Samples were applied to solid-phase extraction cartridges (Bond Elut C18 500 mg; Agilent
Technologies, Mulgrave, VIC, Australia) and washed in 15 mL 15% methanol, 15 mL
double-distilled H2O, and 15 mL hexane. 18R/S-HEPE, 17R/S-HDHA, and RvD2 were
eluted with 10 mL methyl formate, dried under nitrogen and then reconstituted in 100 μL 5
mmol/L ammonium acetate (pH = 9)/methanol (50/50; vol/vol) for analysis by liquid
chromatography–tandem mass spectrometry using a Thermo Scientific TSQ QuantumUltra
triple-quadrupole LC–MS system equipped with an electrospray ionization source (ESI)
operated in the negative ion mode.
2.5. Analysis of omega-6-derived pronociceptive mediators
Omega-6 LA-derived 9- and 13R/S-hydroxy-octadecadienoic acid (9- and 13R/S-HODE), 9-
and 13R/S-oxo-octadecadienoic acid (9- and 13R/S-oxoODE), and n-6 AA-derived 5-, 8-,
9-, 11-, 12-, and 15R/S-hydroxy-eicosatetraenoic acid (5-, 8-, 9-, 11-, 12-, and 15R/S-
HETE) were analyzed as previously described [16,42]. Briefly, plasma (50 mL), internal
standard [15(S)-HETE-d8 (Cayman Chemical), 10 mL of 1000 ng/mL], and sodium
hydroxide were added to glass test tubes, overlaid with argon, and sealed. Lipids were
hydrolyzed at 60°C under argon for 2 hours. Fatty acids were extracted twice by liquid/
liquid extraction using hexane and hexane/isopropanol with 4 M acetic acid, with tubes
capped under argon. The combined hexane layers were dried under nitrogen and then re-
suspended in 200 mL 85% methanol/water (v/v). Fatty acid oxidation products were
quantified using liquid chromatography online electrospray ionization tandem mass
spectrometry (LC/ESI/MS/MS) (Waters 2690 Separations Module, Franklin, MA, USA and
Quattro Ultima, Micromass, Manchester, UK).
2.6. Headache outcomes
The primary clinical outcome was the Headache Impact Test (HIT-6) [25], a commonly
used measure of headache-related disability based on self-reported pain, social functioning,
role functioning, vitality, cognitive functioning, and psychological distress [9,23].
Participants completed the HIT-6 and reported the number of headache days experienced
during the last 4 weeks (Headache Days) immediately before randomization and on the final
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day of the 12-week intervention phase. In addition, participants were instructed to complete
a daily Headache Diary [41] throughout the run-in phase and the dietary intervention phase
(112 days total) recording hourly headache characteristics (rated as mild, moderate, or
severe) and medication use. The following variables were derived from the Headache Diary:
Headache Hours per day, Severe Headache Days (defined as ≥8 hours of mild headache or
any moderate or severe headache), and medication use (vasoactive abortive, acute pain,
adjunctive, preventive).
2.7. Other measures
The Borkovec and Nau credibility questionnaire [12] was completed after the initial in-depth
dietitian counseling session to assess expectation for treatment success. Participants also
reported demographics and completed the MIDAS (migraine disability assessment) [3], a
validated 7-item measure of headache-related function. During the initial study visit, the
study neurologist assessed the number and type of headache-related medications, and
classified CDH as 1) chronic migraine according to International Headache Disorders-2
criteria [53]; 2) CDH with migraine features (eg, unilateral, pulsating, severe, sensory
sensitivity, or aggravated by physical activity) but insufficient for a diagnosis of chronic
migraine; or 3) CDH without migraine features.
2.8. Data analysis
Descriptive statistics were examined for all variables and, if necessary, steps were taken to
account for nonnormal distributions. Statistical testing was 2-tailed at the 5% type I error,
without adjustment for prespecified multiple comparisons. The erythrocyte and headache
outcome analyses were prespecified. Analyses were conducted using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA) and Stata 12 (StataCorp LP, College Station, TX, USA.
We compared the effect of diet group assignment on postintervention headache-related
outcomes (HIT-6, Headache Days per month, Headache Hours per day, Severe Headache
Days) using analyses of covariance adjusted for the baseline values of each outcome.
Missing follow-up values for HIT-6 and Headache Days per month (measured pre- and
postintervention) were filled with baseline values in order to include all randomized
participants in those analyses. For the outcomes that were recorded daily throughout the
study (ie, Headache Hours per day and Severe Headache Days), we analyzed all available
data without imputations using hierarchical models with either a Poisson or logistic
distribution. For example, to model differences across time by diet group on the number of
Headache Hours per day, we used subject-specific mixed-effects regression models with a
Poisson distribution. Since we had 4 weeks of data prior to randomization, we used a linear
spline variable to capture the trajectory of each individual’s baseline Headache Hours per
day with their change in trajectory after randomization. Changes in Headache Hours per day
were calculated based on model-predicted estimates for intervention days 1 and 80. In
addition to the hierarchical model, we also used a Loess smoothing procedure to visualize
the crude trajectory of average Headache Hours per day for each diet group.
For an exploratory analysis of changes in medication use by diet group, we classified
medications into 3 broad categories: acute, preventive, or adjunctive (Supplementary Table
2). These variables were dichotomized (any vs no use per day) because specific medications
and doses were not comparable between individuals. For each category, the proportion of
subjects using any medication on each day after randomization was calculated using
longitudinal logistic models clustering on subject ID. The percent change was calculated
based on model-predicted estimates on intervention days 1 and 80. In an exploratory
manner, we also examined longitudinal changes in vasoactive abortive medication use in
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each group, in the subset of participants using these medications (n = 37) with a subject-
specific mixed-effects regression model (Poisson distribution).
2.9. Power
This was the first trial evaluating a low n-6 plus high n-3 dietary intervention for clinical
pain reduction. Because clinical effect sizes were unknown, sample size calculations were
based on biochemical data from rodents and human epidemiological studies [27,28]. An
estimated 32 subjects per group were needed for 80% power to detect a between-group
difference in the erythrocyte n-6 in HUFA score, with predicted difference of 0.5 and a
maximum SD of 0.5.
3. Results
3.1. Demographics
Sixty-seven subjects were randomized to either the H3-L6 intervention or the L6
intervention (Fig. 2). Of those, 56 (84%) completed the 12-week intervention phase (28 in
each group). Demographic characteristics were comparable between groups (Table 1).
Ninety-three percent had chronic migraine or CDH with migraine features. Participants
reported taking an average of 6 different headache-related medications at the baseline
interview. Expectation of benefit was moderate, with no between-group differences as
measured by the Credibility Scale.
3.2. Dietary and erythrocyte fatty acids
Pre- and postintervention nutrient intakes have been previously published [29] and are
summarized in Table 2. The H3-L6 intervention group achieved the targeted reduction in
dietary n-6 LA, and increases in n-3 EPA and DHA. The L6 intervention group achieved
targeted reductions in dietary n-6 LA and AA, without alterations in n-3 fatty acids. Pre- and
postintervention erythrocyte n-6 and n-3 fatty acids are shown in Table 2. Compared to
baseline, both interventions produced significant reductions in the erythrocyte n-6 in HUFA
score and significant increases in the n-3 Index. Both of these erythrocyte fatty acid indices
changed significantly more in the H3-L6 group compared to the L6 group. The H3-L6
intervention also significantly reduced erythrocyte n-6 AA, while the L6 intervention had no
effect on AA. Both interventions produced comparable, statistically significant reductions in
erythrocyte LA.
3.3. Anti- and pronociceptive n-3 and n-6 derivatives
Pre- and postintervention antinociceptive mediators and pathway markers derived from n-3
fatty acids and pronociceptive mediators derived from n-6 fatty acids are shown in Table 3.
Compared to baseline, both interventions significantly increased n-3 EPA- and DHA-
derived resolvin pathway precursors 18R/S-hydroxy-eicosapentaenoic acid (18-HEPE) and
17R/S-hydroxy-docosahexaenoic acid (17-HDHA), and also significantly reduced a number
of pronociceptive derivatives of both n-6 LA (eg, hydroxy-octadecadienoic acids [HODEs])
and n-6 AA (hydroxyeicosatetraenoic acids [HETEs]). Compared to the L6 intervention, the
H3-L6 intervention produced significantly more pronounced increases in 18-HEPE and 17-
HDHA. Reductions in HODEs and HETEs were comparable in the 2 groups.
3.4. Clinical headache-related outcomes
While both groups showed statistically significant improvements in clinical outcomes
(Headache Days, HIT-6, Headache Hours, Severe Headache Days) compared to the
preintervention phase (Table 4), the H3-L6 intervention produced significantly greater
improvements in all 4 of these clinical outcomes compared to the L6 intervention (Table 4,
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Fig. 3). In intent-to-treat analyses, the H3-L6 intervention produced significantly greater
improvements in the HIT-6 (−7.5 vs −2.1; P < 0.001) and Headache Days per month (−8.8
vs −4.0; P = 0.02) compared to the L6 group. The H3-L6 intervention also significantly
reduced Headache Hours per day (−4.6 vs −1.2; P = 0.01) and the probability of
experiencing a Severe Headache Day (−28% vs −8%; P = 0.02) compared to the L6 group.
Between-group differences in Headache Hours per day became evident at 8 weeks of diet
exposure (P = 0.04), and remained significant thereafter (P = 0.01).
Compared to baseline, the proportion of subjects in the H3-L6 group who used any pain-
related acute or adjunctive medication at 12 weeks was reduced by 37% and 43%,
respectively (P < 0.01) (Fig. 4). Use of preventive medications did not change significantly
during the intervention. In an exploratory analysis of the sub-sample who used vasoactive
abortive medications (n = 37), there was a 33% reduction in use of these migraine-specific
medications (95% confidence interval −52-0) in the H3-L6 group, with no change in the L6
group.
4. Discussion
In this randomized trial, the combination of increasing dietary n-3 fatty acids with
concurrent reduction in n-6 LA (the H3-L6 intervention) produced statistically significant,
clinically relevant improvements in headache hours per day, severe headache days, and
headache-related quality of life compared to baseline, and compared to the n-6-lowering
(L6) intervention. Prior to the intervention, this chronic headache population averaged 23
headache days per month and 10 headache hours per day, despite using an average of 6
different headache-related medications per subject. Hence, the H3-L6 intervention provided
clinical benefit in a population resistant to conventional pharmacological headache
treatment.
This trial compared 2 active interventions that were both hypothesized to have
antinociceptive effects. Both interventions were designed to be equally intensive and were
perceived to be equally credible by participants. Therefore, improvements due to factors
other than the dietary changes (eg, placebo effect, natural history of disease) are expected to
affect both intervention groups equally. In this context, the significantly greater clinical
improvement in the H3-L6 group compared to the L6 group reflects clinical benefit beyond
the placebo effect.
Clinical improvements in the H3-L6 group were not due to increased use of pain
medications. In fact, these improvements were observed despite significant reductions in the
use of vasoactive abortive, total acute, and adjunctive medications compared to baseline.
Improved headache outcomes with concurrent reduction in medication use may be important
given potential side effects of many headache medications [6–8,31,57,59].
4.1. Investigating the biochemical mechanisms of pain reduction
Clinical improvements in the H3-L6 group were accompanied by significantly greater
increases in erythrocyte n-3 EPA and DHA, and a more marked reduction in n-6 AA
compared to the L6 group, which may help explain the significant between-group difference
in pain reduction. The H3-L6 intervention also markedly increased the antinociceptive n-3
derivatives 18-HEPE and 17-HDHA (precursors to E- and D-series resolvins [40,54]) in
circulation. Diet-induced increases in these and perhaps other antinociceptive n-3 derivatives
that were not measured in the present trial, including maresins, protectins, and n-3
monoepoxides [32,34,48,58], may have contributed to the observed clinical improvement in
the H3-L6 group.
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Omega-6 AA, which was significantly reduced in erythrocytes by the H3-L6 but not the L6
intervention, is the biosynthetic precursor to a variety of pronociceptive and vasoactive lipid
mediators implicated in headache pathogenesis [1,2,19,22,56]. Notably, n-6 AA is converted
to 2-series prostaglandins by cyclooxygenase [1], the target of medications commonly
administered for headache relief (nonsteroidal antiinflammatory drugs, aspirin). Thus, the
observed pain reduction produced by the H3-L6 intervention may reflect a combination of
reductions in n-6 AA and its pronociceptive derivatives and increases in n-3 EPA and DHA
and their antinociceptive derivatives.
The H3-L6 intervention also significantly reduced numerous HODE and HETE derivatives
of n-6 LA and n-6 AA, respectively, compared to baseline. Since HODEs and HETEs have
putative pronociceptive properties by acting as endogenous ligands for the vanilloid
(TRPV1) receptor channel (ie, endovanilloids) [20,35,36,56], these biochemical changes
were hypothesized to reduce pain. However, because comparable reductions in a number of
HODEs and HETEs occurred in both groups, these changes are unlikely to account for the
significantly greater clinical benefit of the H3-L6 intervention.
4.2. Is dietary n-6 lowering necessary for antinociception?
The only randomized controlled trial to test n-3 supplementation in a migraine population
showed no clinical benefit [37], despite providing a dose of EPA + DHA comparable to our
H3-L6 intervention. A possible explanation for this discrepancy is that the dietary n-6-
lowering component of our H3-L6 intervention may be necessary to produce maximal
clinical benefit. Although the n-3 supplementation trial in migraineurs did not report
biochemical outcomes [37], n-3 supplementation is known to increase circulating EPA +
DHA and bioactive n-3 derivatives [30], and to reduce AA and bioactive AA derivatives.
The H3-L6 intervention in the present trial differs from previous trials because it not only
increased n-3 fatty acids, but also markedly reduced dietary n-6 LA, which competes with
n-3 fatty acids for hepatic desaturation, tissue incorporation, and enzymatic conversion to
bioactive derivatives [17,24,29,33,39].
4.3. Biochemical effects of the L6 intervention
The L6 intervention provides a rare opportunity to evaluate the biochemical effects of
dietary n-6 lowering without altering dietary n-3 fatty acids in humans [29]. Although
biochemical effects were less pronounced compared to the H3-L6 group, this L6
intervention did significantly alter erythrocyte fatty acids and their bioactive derivatives in a
manner that we hypothesized would reduce pain. As expected, the L6 intervention reduced
erythrocyte n-6 LA and a number of its pronociceptive derivatives compared to baseline.
Unexpectedly, the L6 intervention also reduced a number of pronociceptive HETEs
compared to baseline, despite no change in their precursor n-6 AA in erythrocytes.
Importantly, the L6 intervention also increased erythrocyte EPA + DHA and their
antinociceptive derivatives 18-HEPE and 17-HDHA compared to baseline. Since dietary n-3
fatty acids were not altered in this group, these increases in circulating n-3 fatty acids and
their derivativeswere likely due to reduced metabolic competition with n-6 fatty acids
[17,24,29,33,39].
These putative antinociceptive biochemical changes in the L6 group were accompanied by
statistically significant (but modest) pain reduction compared to baseline. However,
regression to the mean, the natural course of the disorder, and/or the placebo effect may
have accounted for most or all of these clinical improvements [11]. Regardless of whether
the L6 intervention provided any antinociceptive effects, the significantly greater clinical
improvement seen in the H3-L6 group compared to the L6 group demonstrates clinical
benefit beyond the placebo effect.
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4.4. Strengths and limitations
A strength of the present trial was the use of an active intervention as a comparison group
for the H3-L6 intervention. A common limitation of dietary trials is the use of a
nonintervention control group in which subjects are simply advised to continue their
habitual diets, without equivalent investigator interaction or food provision. Since the L6
intervention was equally intensive and perceived to be equally credible by participants, it
likely provided a better control for the placebo effect than a nonintervention control.
Nevertheless, the clinical effects of the H3-L6 intervention should also be evaluated in
comparison to a control intervention providing habitual intakes of targeted dietary fatty
acids. Care should be taken to ensure that such a control intervention is equally intensive
and credible.
The combination of intensive dietary guidance and provision of study foods with laboratory-
analyzed fatty acid composition allowed for greater control over nutrient intake compared to
supplementation trials. Demonstration of adherence via dietary recalls and erythrocyte fatty
acid analyses [29] is an improvement over a previous n-3 supplementation trial in
migraineurs [37]. The demonstration of significant alterations in fatty acids and lipid
mediators along the proposed causal chain linking diet to physical pain, with consistent
directionality in both clinical and biochemical end points, is another strength of the present
trial. In addition to the pre- and postintervention questionnaires, our use of longitudinal data
from the daily Headache Diary allowed for a more detailed comparison of the clinical
trajectory of the 2 groups. The erythrocyte fatty acid alterations and the downward trajectory
in Headache Hours continued between intervention weeks 8 and 12 (Fig. 3), suggesting that
continuation of the H3-L6 diet beyond 12 weeks might produce even more marked benefit.
This trial also had important limitations. Although there was sufficient power to detect
between-group differences in the targeted biochemical and clinical outcomes, the present
trial was relatively small and should be replicated in a larger trial. As in other outpatient diet
trials, the targeted fatty acids could not be altered as independent variables. Therefore, it is
possible that changes in other nutrients could have contributed to the favorable effects of the
H3-L6 intervention. While the lipid mediators measured here have been linked to physical
pain by plausible mechanisms, the present trial cannot establish whether changes in any
specific mediator contributed to the observed clinical improvement. Diet-induced changes in
n-3 and n-6 derivatives with vasoactive properties [2,15,21,49,55] in circulation may have
contributed to headache reduction via direct actions on the vasculature. However, future
trials are needed to establish whether comparable diet-induced biochemical alterations are
possible in other tissues implicated in headache pathogenesis, such as trigeminal nerve,
brain, and skeletal muscle.
4.5. Generalizability
Biochemical derangements targeted by the H3-L6 intervention have been implicated in
several headache types [2,26] and numerous other pain syndromes [13,22,44]. Therefore, a
logical next step would be to evaluate the efficacy of the H3-L6 intervention in a more
homogeneous headache population such as chronic migraine or chronic tension-type
headache, and in other populations with chronic pain. Since the present trial was conducted
in a population with high n-6 LA and low n-3 EPA + DHA consumption, some caution
should be used when extrapolating results to populations with different dietary
characteristics. Finally, the magnitudes of the observed dietary changes and biochemical and
clinical effects are not necessarily generalizable to populations with less severe or less
frequent pain.
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Targeted dietary manipulation of n-3 and n-6 fatty acids reduced pain and improved quality
of life in this population with chronic headaches, and could represent a novel strategy for
treating chronic pain in general. Future trials evaluating clinical efficacy and elucidating
biochemical mechanisms in populations with chronic pain are warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Proposed mechanisms linking targeted alterations in n-3 and n-6 fatty acids with pain
reduction. This figure summarizes hypothetical mechanisms linking n-3 and n-6 fatty acids
to pain reduction, including representative mediators measured in the present trial (9-HODE
and Resolvin D2) as well as mediators that were not measured in this trial (Prostaglandin E2
and Resolvin E1). (A) Targeted dietary alterations increase the abundance of n-3 EPA and
DHA (blue) and decrease the abundance of n-6 LA and AA (red) in fatty acid precursor
pools, including the membranes of endothelial cells, platelets, immune cells, glia, myelin,
and neurons. (B) These changes in precursor abundance alter the concentrations of n-3 and
n-6 derived antinociceptive and pronociceptive mediators, including E- and D-series
resolvins, maresins, prostaglandins, endovanilloids, and endocannabinoids. (C) Changes in
the milieu of lipid mediators alter the activities of receptors involved in pain signaling,
including the vanilloid receptor (TRPV1) and several G-protein coupled receptors (eg, E-
prostanoid receptors, resolvin receptors, cannabinoid receptors). (D) Increases in
antinociceptive mediators and decreases in pronociceptive mediators reduce pain signaling
in the trigeminovascular system and central pain signaling pathways. EPA, eicosapentaenoic
acid; DHA, docosahexaenoic acid; LA, linoleic acid; AA, arachidonic acid; 9-HODE, 9-
hydroxy-octadecadienoic acid.
Ramsden et al. Page 14















Ramsden et al. Page 15














Mean daily Headache Hours by dietary intervention group. Graph depicts the average
number of Headache Hours calculated for each day according to intervention group. A
Loess smoothing procedure was employed to visualize trends. Participants in the 2 groups
provided equivalent amounts of Headache Diary data after randomization (2145 total days
of records in the L6 group and 2175 in the H3-L6 group).
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Change in medication use over the course of the intervention by diet group. Acute
medications included vasoactive abortive medications, acute opioids, and nonsteroidal
antiinflammatory drugs; Adjunctive medications included antiemetics, anxiolytics, sleep
aids/hypnotics, and muscle relaxants. All changes depicted in Fig. 4 were significantly
changed compared to baseline. There was no significant change in the use of Preventive
medications (eg, anticonvulsants, antidepressants, vasoactive preventives, long-acting
opiates) over time in either group.
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Table 1





Age, years: Mean (SD) 41 (13.4) 42 (11.1)
Female, n (%) 28 (84.8) 30 (88.2)
White race, n (%) 28 (84.8) 30 (88.1)
Married, n (%) 19 (57.6) 19 (55.9)
Education, n (%)
 High school 2 (6.1) 2 (6.2)
 Attended college 18 (54.5) 17 (53.1)
 Master’s degree or higher 13 (40.6) 13 (39.4)
Employment, n (%)
 Employed/student 26 (78.8) 23 (69.7)
 Retired/caretaker 3 (9.1) 3 (9.1)
 Disabled/unemployed 4 (12.1) 7 (20.0)
Headache categorya, n (%)
 Chronic migraine 26 (78.8) 24 (70.6)
 CDH with migraine features 6 (18.2) 6 (17.6)
 CDH without migraine features 1 (3.0) 4 (11.8)
Headaches managed by neurologist, n (%) 24 (72.7) 24 (70.6)
Age at first headache, median (IQR) 15 (10) 18 (18)
Patients reporting 2 or more headache-related medications, n (%)
 Acute medicationsb 31 (93.9) 29 (85.3)
 Preventive medicationsb 13 (39.4) 13 (38.2)
 Adjunctive medicationsb 8 (24.2) 12 (35.3)
Total number of different headache-related medications reported, mean (SD) 6.4 (3.4) 5.6 (3.3)
MIDAS (Headache-related disability), Median (95% CI)c 43 (28, 59) 34 (24, 47)
Credibility Scale (Borkovec & Nau) (range 0–45), mean (SD) 28.3 (5.5) 27.1 (3.8)
CDH, chronic daily headache; IQR, interquartile range; MIDAS, migraine disability assessment; CI, confidence interval.
a
Subjects classified as chronic migraine met International Headache Disorders-2 criteria. Subjects classified as CDH with migraine features had
some characteristics of migraine (eg, unilateral, pulsating, severe, sensory sensitivity, or aggravated by physical activity) but did not meet all
criteria needed for chronic migraine diagnosis. Subjects classified with CDH without migraine features had no evidence of migraine.
b
Headache medication categories are shown in Supplementary Table 2.
c
95% confidence interval around the median per binomial-based method in Stata 12.
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Table 4
Clinical effects of H3-L6 vs L6 interventions in chronic headache patients.
H3-L6 intervention (n = 33)
Mean (95% CI)





Headache Impact Test (HIT-6)a
 Baseline 61.0 (59.5, 62.5) 60.6 (58.7, 62.6)
 Follow-up 53.5 (50.8, 56.2) 58.5 (56.3, 60.8) −5.4 (−8.2, −2.6) <0.001
 Pre- to postchange −7.5 (−4.9, −10.2) −2.1 (−0.99, −3.2)
 P-value c <0.001 <0.001
Headache Days per montha
 Baseline 23.3 (20.9, 25.8) 23.2 (20.2, 25.8)
 Follow-up 14.5 (10.8, 18.2) 19.0 (15.4, 22.7) −4.8 (−8.9, −0.7) 0.02
 Pre- to postchange −8.8 (−5.4, −12.2) −4.0 (−1.45, −6.55)
 P-valuec <0.01 <0.01
Headache Hours per dayb
 Baseline 10.2 (8.4, 12.3) 9.8 (8.1, 11.8)
 Follow-up 5.6 (4.3, 7.3) 8.6 (7.0, 10.6) −45% (−53%, −9%) 0.01
 Pre- to postchange −44% (−49%, −39%) −13% (−18%, −8%)
 P-valuec <0.001 <0.001
Percent (95% CI) Percent (95% CI) Percent (95% CI)
Probability of experiencing a Severe Headache dayb
 Baseline 66 (55, 77) 68 (58, 79)
 Follow-up 38 (24, 52) 61 (47, 73) −23 (−42, −4.1) 0.02
 Pre- to postchange −28 (−44, −13) −7.8 (−15, −1)
 P-value c 0.02 0.03
CI, confidence interval.
a
Measured at baseline and at intervention end. Last values of each randomized subject brought forward for “intent-to-treat” analysis.
b
Measured daily throughout 4-week preintervention and 12-week intervention phase. Hierarchical linear models used all available data for each
randomized participant.
c
Indicates paired sample t-test.
d
Between-group difference P-values are based on analysis of covariance comparing postintervention values controlling for baseline values.
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